SCHEMBL19355469

SCHEMBL19355469

CNC(=O)c1ccnc2c(CCNc3cc(-c4cnn(C)c4)ncn3)cccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 4/20 0.44
LRRK2 Q5S007 1/20 0.44
HSP90AA1 P07900 7/20 0.39
USP2 O75604 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
ALOX15 P16050 2/20 0.39
CYP2C19 P33261 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
HSD17B10 Q99714 1/20 0.39
PIM1 P11309 1/20 0.38
MEN1 O00255 1/20 0.38
CYP2C9 P11712 1/20 0.38
KMT2A Q03164 1/20 0.38
JAK1 P23458 3/20 0.37
JAK3 P52333 3/20 0.37
JAK2 O60674 2/20 0.37
MET P08581 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19355276 0.86 CYP1A2 (0.52) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19355271 0.86 PRKDC (0.43) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19905362 0.86 CYP1A2 (0.41) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19355399 0.85 CYP1A2 (0.42) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19905089 0.85 CYP1A2 (0.40) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19355460 0.85 CYP1A2 (0.44) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19355128 0.85 CYP1A2 (0.41) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19355476 0.85 FAAH (0.42) USP2ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19355135 0.85 CREBBP (0.41) CREBBPLRRK2USP2ALDH1A1CYP1A2
SCHEMBL19819885 0.85 CYP1A2 (0.40) USP2ALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3057959-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2018-02-28 EP disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK CREBBP 1268/4885LRRK2 1501/4885HSP90AA1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.